Baird Medical Investment Holdings Limited announced that Mark Saxton will become chief executive officer of its U.S. subsidiary, taking charge of all U.S. operations. Saxton brings more than 25 years of commercial leadership in the medical device sector, having led the U.S. commercialization of intravascular radio‑frequency ablation products at VNUS Medical Technologies and guided NeuroPace through a successful IPO that raised $117.3 million.
Saxton’s track record of scaling high‑growth med‑tech businesses underpins Baird’s strategy to deepen its footprint in the United States. At VNUS, he doubled annual revenue from $49 million to over $100 million in just over two years before the company was acquired by Covidien for $512 million. His experience in pricing, channel development and regulatory navigation is expected to accelerate adoption of Baird’s FDA‑cleared microwave ablation platform across oncology and endocrine indications.
Baird’s microwave ablation system, which uses microwave energy to denature tumor cells, is already deployed in more than 30 U.S. hospitals and clinics, including Mayo Clinic, Columbia University Medical Center and UCSF Medical Center. The company’s gross profit margin of 88 % and a trailing‑twelve‑month revenue of $37.04 million demonstrate strong pricing power and efficient cost structure, while a low P/E ratio of 5.09 suggests the stock may be undervalued relative to peers.
Chairwoman Haimei Wu said, “Mark’s proven track record of taking novel technologies to market leadership, deep experience in the thermal ablation space and his history of creating significant shareholder value make him the ideal leader for this critical phase of our growth.” Saxton added, “I am honored to join Baird Medical at this pivotal moment. Baird’s microwave ablation platform offers meaningful advantages in minimally invasive care, and I look forward to advancing our U.S. commercial strategy and expanding access for patients while building lasting value for shareholders.”
Baird’s U.S. expansion plan includes opening a new regional office in San Francisco and pursuing additional contracts with academic medical centers and specialty hospitals. The company also recently entered the Egyptian market, performing its first microwave ablation procedure there, signaling a broader global growth strategy. With Saxton at the helm, Baird aims to capture a larger share of the U.S. market for microwave ablation, which is projected to grow as minimally invasive therapies gain traction in oncology and endocrine treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.